MicroRNA let-7g and let-7i inhibit hepatoma cell growth concurrently via downregulation of the anti-apoptotic protein B-cell lymphoma-extra large

LINGJIAO WU1,* , QIANGFENG WANG2*, JIAN YAO1, HAN JIANG2, CHENG XIAO2 and FUSHENG WU2

1State Key Laboratory for Diagnosis and Treatment of Infectious Diseases; 2Department of Surgical Oncology, The First Affiliated Hospital, Zhejiang University, Hangzhou, Zhejiang 310003, P.R. China

Received February 4, 2014; Accepted October 15, 2014

DOI: 10.3892/ol.2014.2706

Abstract. Let-7 family members have been identified as tumor-suppressing microRNAs, which are important in human hepatocellular carcinoma (HCC). These family members may function differently as a result of different base sequences at the 3’end. The aim of this study was to determine the antitumor effects of miR-let-7g/i (let-7g/i) on HCC cells and to investigate whether let-7g and let-7i have a combinatorial effect on HCC. The expression levels of let-7g/i in hepatoma cells were determined by quantitative reverse transcription polymerase chain reaction. In addition, a 5-ethynyl-2’-deoxyuridine retention assay and flow cytometry analysis were used to detect the effect of let-7g/i on the proliferation and apoptosis of BEL-7402 cells, respectively. The expression of anti-apoptotic protein B-cell lymphoma-extra large (Bcl-xL) was analyzed using western blot analysis. The results revealed that the expression levels of let-7g/i were significantly decreased in HCC cell lines when compared with L-02 cells. Furthermore, the overexpression of let-7g/i significantly suppressed DNA replication, inhibited cell proliferation and promoted apoptosis of BEL-7402 hepatoma cells. The expression of the anti-apoptotic protein, Bcl-xL, was inhibited by the combined role of let-7g and let-7i. We hypothesize that let-7g and let-7i exhibit a concurrent effect to regulate cell proliferation and the apoptosis of hepatoma cells, and this function is mediated by the Bcl-xL protein.

Introduction

MicroRNAs (miRNAs), which are small, non-coding RNAs that are 18-25 nucleotides in length, are involved in gene regulation. miRNAs bind to the 3’untranslated region (3’UTR) of target mRNAs to inhibit translation or induce the degradation of mRNA (1-3). A previous study revealed that ~50% of human miRNAs are located at fragile sites of the genome, which are associated with cancer (4). This indicates that miRNAs may be crucial for cancer progression (1,5). Full-scale analysis of miRNomes has indicated that only 0.9% of miRNAs are expressed abundantly in the normal human liver; however, these miRNAs account for 88.2% of all miRNAs in the liver, and four of the first nine miRNAs belong to the let-7 family (6). Furthermore, let-7 family members have been found to be downregulated in a number of human cancers, including lung, colon, ovarian, uterine leiomyoma and breast cancer, as well as hepatocellular carcinoma (HCC) (7-13), indicating that let-7 miRNAs may present potential tumor suppressors. It has been reported that let-7c induces apoptosis and inhibits HCC cell proliferation in vitro (11). In humans, 12 genomic loci have been identified, which encode the let-7 family members, including let-7a-1, -2, -3, let-7b, let-7c, let-7d, let-7e, let-7f-1, -2, let-7g, let-7i and mir-98 (3). These members share the same nucleotide sequence between the second and eight consecutive nucleotides at the 5’end, which are termed ‘seed sequences’, that determine their target genes (Fig. 1A; miRBase v.18.0; http://www.mirbase.org/search.shtml) (14); therefore, it has been hypothesized that each member exhibits the same role. However, the difference in nucleotides at the 3’end indicates that let-7 families are not functionally equivalent with regard to combination strength and efficiency of interactions with target genes (15,16). It has been reported that members of the let-7 family, mir-48, mir-84 and mir-241, which have the same seed sequences but different nucleotide sequences at the 3’end, exhibit specific and redundant roles in the regulation of developmental timing in Caenorhabditis elegans (16). An additional study has also indicated that the degree of complementarity between the 3’end of the miRNA and target gene is the structural basis of the same family miRNAs exerting different functions (15).
Bioinformatics analysis (DIANA Lab and PICTAR) (11) indicates that the anti-apoptotic protein B-cell lymphoma-extra large (Bcl-xL) is a target gene of let-7g and let-7i. The aim of the present study was to investigate whether the let-7 family members exhibit specific and/or overlapping roles in human HCC as observed in Caenorhabditis elegans. Thus, the anti-tumor effect of let-7g/i on HCC was investigated, and whether let-7g and let-7i exhibit a concurrent effect on HCC was determined. Furthermore, the effect of let-7g/i on the Bcl-xL protein in HCC cells was analyzed.

Materials and methods

Cell culture. The human L-02 liver cell line and hepatoma cell lines, SMMC-7721 and Bel-7402, were purchased from Shanghai Institutes for Biological Sciences of Chinese Academy of Sciences (Shanghai, China). The L-02 and SMMC-7721 cell lines were cultured in endotoxin-free Dulbecco’s modified Eagle’s medium with 10% fetal bovine serum (Gibco Life Technologies, Carlsbad, CA, USA). The BEL-7402 cell line was cultured in RPMI 1640 medium with 10% (vol/vol) fetal bovine serum (Gibco Life Technologies). The cell lines were incubated at 37°C in an atmosphere of 5% CO2.

Transfection. The miR-let-7g/i (let-7g/i) agomir (an engineered miRNA mimic) and a negative control (similar to agomir(let-7g/i) but with a scramble seeding sequence) were obtained from Guangzhou RiboBio Co., Ltd., (Guangzhou, China). Cells were plated at 45-50% confluence. The let-7g/i agomir and/or let-7g agomir negative control were transfected into the human hepatoma BEL-7402 cell line using transfection reagent Lipofectamine™ 2000 in Opti-MEM (Gibco Life Technologies), according to the manufacturer's instructions. One negative control group, which was transfected with 100 nm let-7g agomir, 100 nm let-7i agomir or co-transfected with 50 nm let-7g and 50 nm let-7i agomir (let-7g + let-7i) were used. The expression levels of let-7g and let-7i were quantified using the SYBR Premix Ex Taq™ II (Perfect Real Time) kit (Takara Bio, Inc., Otsu, Japan), 24 h after transfection. Briefly, 20 µl PCR reaction mixture was pre-heated at 95°C for 30 sec, followed by 40 cycles at 95°C for 5 sec and 60°C for 34 sec.

5-ethynyl-2’-deoxyuridine (EdU) retention assay. An EdU assay was performed using the Cell Light EdU DNA imaging kit (Guangzhou RiboBio Co., Ltd.)to measure the effects of let-7g/i on cellular proliferation. The EdU assay was performed 48 h after cells were transfected with let-7g/i agomir. Cells were seeded in 96-well plates and exposed to 100 nm let-7g agomir, 100 nm let-7i agomir or co-transfected with 50 nm let-7g and 50 nm let-7i agomir (let-7g + let-7i) were used. The expression levels of let-7g and let-7i were quantified using the SYBR Premix Ex Taq™ II (Perfect Real Time) kit (Takara Bio, Inc., Otsu, Japan), 24 h after transfection. Briefly, 20 µl PCR reaction mixture was pre-heated at 95°C for 30 sec, followed by 40 cycles at 95°C for 5 sec and 60°C for 34 sec.

miRNA target predictions. The algorithms DIANA Lab (http://diana.cslab.ece.ntua.gr/), Pictar (http://pictar.mdc-berlin.de/), and TargetScan (http://www.targetscan.org/) were used to predict let-7 family members that could potentially bind to Bcl-xL mRNA.

Cell apoposis assay. Apoptosis assay was performed with Annexin V-fluorescein isothiocyanate Apoptosis Detection Kit I (BD Pharmingen, San Diego, CA, USA) 48 h following transfection, according to the manufacturer's instructions. The cell suspension (100 µl) was incubated with 5 µl Annexin V and 5 µl propidium iodide (BD Pharmingen) at room temperature for 10 min. Finally, 400 µl binding buffer was added to each tube and the cells were suspended. The treated cells were analyzed by fluorescence-activated cell sorting using a BD LSR II flow cytometry kit (BD Pharmingen).

Real-time PCR. Total RNA was isolated from cells using the mirVana miRNA isolation kit (Ambion Life Technologies, Carlsbad, CA, USA) according to the manufacturer's instructions. A total of 10 ng total RNA was reversely transcribed using the TaqMan MicroRNA Reverse Transcription kit (Applied Biosystems, Foster City, CA, USA). Quantitative PCR was analyzed using SYBR Premix Ex Taq™II and the Viia7 real-time PCR system (Applied Biosystems). U6 small nuclear RNA (snRNA) was used to normalize let-7g/7i expression levels. Primers for let-7g (cat no. miRQ000414-1-1)/7i (cat no. miRQ000415-1-1) and U6 (cat no. MQP-0201) snRNA were purchased from RiboBio (Guangzhou, China).

Western blot analysis. Total protein was isolated from cells using cell lysis buffer (Cell Signaling Technology, Inc.) after transfection for 48 h. The protein levels were quantified using a DC Protein Assay (Bio-Rad Laboratories, Hercules, CA, USA). Protein samples (30 µg) were loaded on a 12% SDS-PAGE gels and electroblotted to Immob-Blot polyvinylidene fluoride membranes (Millipore, Billerica, MA, USA). Membranes were blocked and probed with a monoclonal rabbit anti-human Bcl-xL antibody (1:1,000; Epitomics Inc, Burlingame, CA, USA), then washed with Tris-buffered saline and Tween 20 (50 mM Tris, 150 mM NaCl, 0.1% Tween-20; pH 7.6; Sigma-Aldrich), and incubated with a secondary horseradish peroxidase-conjugated goat anti-rabbit antibody (1:5,000; Hangzhou Hu’an Biotechnology Co., Ltd., Hangzhou, China). Protein levels were normalized to total glyceraldehyde 3-phosphate dehydrogenase (GAPDH) using a mouse anti-human GAPDH antibody (1:1,000; Abcam, Cambridge, UK). The intensity of each protein band was quantified by Quantity One version 4.62 software (Bio-Rad Laboratories).

Statistical analysis. Data are presented as the mean ± standard deviation of four independent experiments. Statistical analyses were performed using Microsoft Excel and SPSS software, version 16.0 (SPSS Inc., Chicago, IL, USA). Quantitative PCR data were analyzed as follows: U6 snRNA was used to normalize let-7g/i expression levels. Let-7g/i expression levels were measured using the threshold cycle (Ct), and the fold-change in expression was calculated as 2^ΔΔCt. The relative expression of let-7g/i in hepatoma cell lines was calculated using the following formula: ΔΔCt = (Ctlet-7g/i - CtU6)
cancer - (Ctlet-7g / CtU6) L-02. The relative expression of let-7g/i after transfection was calculated using the equation: 
\[ \Delta \Delta Ct = (Ctlet-7i / CtU6) \text{post-transfection} - (Ctlet-7g / CtU6) \text{pro-transfection}. \]

Factorial analysis of variance was used to analyze the interaction between let-7g and let-7i in the EdU retention assay and cell apoptosis assay. P<0.05 was considered to indicate a statistically significant difference.

Results

let-7g, let-7i and Bcl-xL expression in hepatoma cells. let-7g/i expression was decreased in SMMC-7721 and BEL-7402 hepatoma cells when compared with the immortalized liver cell L-02 line (P<0.01) (Fig. 2A).

Bioinformatics analysis (DIANA Lab and PICTAR) predicted that the anti-apoptotic protein Bcl-xL is a target gene of let-7g and let-7i, with a potential binding site on the 3'UTR of Bcl-xL (Fig. 1B). In addition, a previous study demonstrated that Bcl-xL is the direct target of let-7c and -7g in Huh7 hepatoma cells (11). In this study, Bcl-xL protein expression was detected by western blot analysis and it was found that the protein expression of Bcl-xL was increased in the two hepatoma cell lines, when compared with the L-02 cell line (P<0.01) (Fig. 2B).

Expression levels of let-7g and let-7i in the BEL-7402 cell line following transfection. The fold-changes in let-7g/i levels in the HCC BEL-7402 cell line were detected following transfection with agomirs or the negative control. The expression levels of let-7g in the groups transfected with let-7g or co-transfected with let-7g and let-7i were 2,073- and 441-fold those of the control group, respectively. The expression levels of let-7i in the groups transfected with let-7i and co-transfected with let-7g and let-7i were 1,303- and 605-fold those of the control group, respectively (Fig. 2C).

Overexpression of let-7g/i inhibits hepatoma cell proliferation. The BEL-7402 cells were transfected with let-7g/i agomir or the negative control to investigate the effects of let-7g/i agomir on HCC cell growth. Hoechst staining nuclei in the experimental groups were dense and contracted (Fig. 3A). DNA replication activity in the groups transfected with the negative control, let-7g and let-7i were 2,073- and 441-fold those of the control group, respectively. The expression levels of let-7i in the groups transfected with let-7i or co-transfected with let-7g and let-7i were 1,303- and 605-fold those of the control group, respectively (Fig. 2C).

Overexpression of let-7g/i inhibits hepatoma cell proliferation. The BEL-7402 cells were transfected with let-7g/i agomir or the negative control to investigate the effects of let-7g/i agomir on HCC cell growth. Hoechst staining nuclei in the experimental groups were dense and contracted (Fig. 3A). DNA replication activity in the groups transfected with the negative control, let-7g and let-7i were 2,073- and 441-fold those of the control group, respectively. The expression levels of let-7i in the groups transfected with let-7i or co-transfected with let-7g and let-7i were 1,303- and 605-fold those of the control group, respectively (Fig. 2C).
Let-7g + 7i group was inhibited (P<0.05) (Fig. 3B), indicating that there may be a combinatorial effect between let-7g and let-7i.

Overexpression of let-7g/i induces hepatoma cell apoptosis. BEL-7402 cells were transfected with let-7g/i agomir or the negative control to investigate the effects of let-7g/i on cell apoptosis. The results revealed that transfection with let-7g/i agomir increased the percentage of apoptotic cells in the BEL-7402 cell line (Fig. 3C). The rates of apoptosis in the groups transfected with let-7g, let-7i and let-7g + 7i were 14.3, 7.7 and 14.1%, respectively, which were significantly greater than the rate in the control group (2.2%) (P<0.05; Fig. 3D).

Co-transfection with Let-7g and let-7i downregulates the expression level of Bcl-xL. The expression of the anti-apoptotic protein, Bcl-xL, was analyzed by western blot analysis (Fig. 4A). The gray-value quantitative analysis showed that Bcl-xL protein expression in BEL-7402 cells was markedly decreased after co-transfection with let-7g and let-7i compared with that in the control. However, the protein expression was not significantly influenced after transfection with let-7g or let-7i (Fig. 4B), suggesting that let-7g and let-7i exert a combined effect on Bcl-xL protein in BEL-7402 cells.

Discussion

The correlation between miRNA mutation or altered expression and various human cancers indicates that miRNAs may function as tumor suppressors or oncogenes and, thus, they are referred to as oncomirs (4). It has been demonstrated that the let-7 family are important tumor suppressor genes (17). In this

---

**Figure 3. Effects of overexpression of let-7g/i on the proliferation and apoptosis of BEL-7402 cells.** (A) The cells were marked by 5-ethyl-2'-deoxyuridine after transfection for 48 h, then fixed and stained using Apollo and Hoechst 33342. Finally, the cells were observed by fluorescence microscopy and three fluorescent microscope images were captured randomly for each group. (B) Cell count was analyzed by Image-Pro Plus 6.0 software and data analysis was performed using factorial analysis of variance with SPSS software, version 16.0. (C) Cell apoptosis was evaluated using Annexin V-fluorescein isothiocyanate/propidium iodide double staining. Early and late apoptotic cells were combined as Annexin V-positive cells that were used to calculate the percentage of apoptotic cells. (D) Data analysis was performed using factorial analysis of variance with SPSS software, version 16.0. Ctrl, control.

**Figure 4.** (A) Effects of overexpression of let-7g/i on the Bcl-xL protein. (B) The relative expression of Bcl-xL by gray-value quantitative analysis. Bcl-xL, B-cell lymphoma-extra large; Ctrl, control.
study, the expression of let-7g/i was found to be significantly decreased in HCC cells when compared with the L-02 cell line. These results are consistent with those of Shimizu et al., which demonstrated that the expression of let-7b, -7g, -7i, -7d, -7a, -7c and 7e was downregulated in Huh7 cells when compared with normal hepatocytes (11). A similar result was found in the present study, however, different methods and cell lines were used. In addition, the effects of let-7g/i on the biological behavior of hepatoma cells were investigated, and it was found that the overexpression of let-7g/i significantly inhibited the cell proliferation and promoted the cell apoptosis of BEL-7402 cells. miRNAs have been identified as a class of regulatory RNAs in numerous biological processes (18-20). The loss of let-7 activity induces abnormal development in Caenorhabditis elegans (21). In addition, the LIN28/let-7 pathway exhibits a critical pathobiological role in malignant germ cell tumors (22). Furthermore, enforced expression of let-7b inhibited breast cancer cell motility and affected actin dynamics (13).

In this study, co-transfection with let-7g and let-7i was found to exhibit an enhanced effect on BEL-7402 cell proliferation and apoptosis, when compared with the effect of let-7g or let-7i alone. These results indicate that let-7g and let-7i exhibit a combinatorial role in suppressing HCC progression. According to a previous study, the let-7 family members mir-48, mir-84 and mir-241, function together to control the L2-to-L3 transition, likely by base pairing to complementary sites in the hbl-1 3' UTR, indicating that let-7 family miRNAs function in combination to affect early and late developmental timing decisions (16). Different target genes may be regulated by a single miRNA, and multiple miRNAs may also function together to regulate one or several gene pathways. These regulatory pathways are hypothesized to affect the development of cancer (1,23).

Let-7 miRNAs act as tumor suppressors by modulating major oncopgenes, including high mobility group protein (10,24), ras (25) and caspase-3 (26). Bcl-XL is a direct target gene of let-7, which was also confirmed by a previous molecular study (11). This previous study demonstrated that the overexpression of let-7c or let-7g led to a marked decrease in Bcl-XL expression in Huh7 and HepG2 hepatoma cell lines (11). The present study also showed that Bcl-XL protein expression in the BEL-7402 hepatoma cell line was significantly decreased following combined transfection with let-7g and let-7i. However, the Bcl-XL protein expression was not significantly influenced by transfection with let-7g or let-7i alone. These results indicated that let-7g and let-7i may exhibit a coordinated effect on the Bcl-XL protein. Two different nucleotides have been identified at the 3'end of let-7g and let-7i base sequences, resulting in different binding sites and modes with Bcl-XL mRNA 3'UTR (Fig. 1B). The two miRNAs augment each other to regulate the Bcl-XL protein. Therefore, the combinatorial role of let-7g and let-7i led to the downregulation of Bcl-XL protein.

In conclusion, let-7g and let-7i exhibit a combined effect to regulate hepatoma cell proliferation and apoptosis, and this function is hypothesized to be mediated via the Bcl-XL protein.

Acknowledgements

This study was supported by the National High-Tech 863 Program (grant no. 2008AA02Z109) and the National Natural Science Foundation of China (grant no. 81272354).

References

1. Lujambio A and Lowe SW: The microcosmos of cancer. Nature 482: 347-355, 2012.
2. Bartel DP: MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116: 281-297, 2004.
3. Roush S and Slack FJ: The let-7 family of microRNAs. Trends Cell Biol 18: 505-516, 2008.
4. Esquela-Kerscher A and Slack FJ: Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer 6: 259-269, 2006.
5. Gregory RI and Shiekhattar R: MicroRNA biogenesis and cancer. Cancer Res 65: 3509-3512, 2005.
6. Hou J, Lin L, Zhou W, et al.: Identification of miRNomes in human liver and hepatocellular carcinoma reveals miR-199a/b-3p as therapeutic target for hepatocellular carcinoma. Cancer Cell 19: 232-243, 2011.
7. Yamaihara N, Cuplen N, Bowman E, et al.: Unique microRNA molecular profiles in late cancer diagnosis and prognosis. Cancer Cell 9: 189-198, 2006.
8. Akao Y, Nakagawa Y and Naoe T: let-7 microRNA functions as a potential growth suppressor in human colon cancer cells. Biol Pharm Bull 29: 903-906, 2006.
9. Nam EJ, Yoon H, Kim SW, et al.: MicroRNA expression profiles in serous ovarian carcinoma. Clin Cancer Res 14: 2690-2695, 2008.
10. Peng Y, Laser J, Shi G, et al.: Antiproliferative effects by Let-7 repression of high-mobility group A2 in uterine leiomyoma. Mol Cancer Res 6: 663-673, 2008.
11. Shimizu S, Takehara T, Hikita H, et al.: The let-7 family of microRNAs inhibits Bcl-XL expression and potentiates sorafenib-induced apoptosis in human hepatocellular carcinoma. J Hepatol 52: 698-704, 2010.
12. Zhu XM, Wu LJ, Xu J, Yang R and Wu FS: Let-7c microRNA expression and clinical significance in hepatocellular carcinoma. J Int Med Res 39: 2323-2329, 2011.
13. Hu X, Guo J, Zheng L, et al.: The heterochronic microRNA let-7 inhibits cell motility by regulating the genes in the actin cytoskeleton pathway in breast cancer. Mol Cancer Res 11: 240-250, 2013.
14. Doench JG and Sharp PA: Specificity of microRNA target selection in translational repression. Genes Dev 18: 504-511, 2004.
15. Brennecke J, Stark A, Russell RB and Cohen SM: Principles of microRNA-target recognition. PLoS Biol 3: e85, 2005.
16. Abbott AL, Alvarez-Saavedra E, Miska EA, et al.: The let-7 MicroRNA family members mir-48, mir-84, and mir-241 function together to regulate developmental timing in Caenorhabditis elegans. Dev Cell 9: 403-414, 2005.
17. Johnson CD, Esquela-Kerscher A, Stefani G, et al.: The let-7 microRNA represses cell proliferation pathways in human cells. Cancer Res 67: 7173-7172, 2007.
18. Inui M, Martello G and Piccolo S: MicroRNA control of signal transduction. Nat Rev Mol Cell Biol 11: 252-263, 2010.
19. Calin GA and Croce CM: MicroRNA signatures in human cancers. Nat Rev Cancer 6: 557-866, 2006.
20. Nicoloso MS, Spizzo R, Shimizu M, Rossi S and Calin GA: MicroRNAs-the micro steering wheel of tumour metastases. Nat Rev Cancer 9: 293-302, 2009.
21. Hunter SE, Finnegan EF, Zisoulis DG, et al.: Functional genomic analysis of the let-7 regulatory network in Caenorhabditis elegans. PLoS Genet 9: e1003353, 2013.
22. Murray MJ, Saini HK, Siegler CA, et al.: LIN28 Expression in malignant germ cell tumors downregulates let-7 and increases oncogene levels. Cancer Res 73: 4872-4884, 2013.
23. Bueno MJ, Gomez de Cedron M, Gomez-Lopez G, et al.: Combinatorial effects of microRNAs to suppress the Myc oncogenic pathway. Blood 117: 6255-6266, 2011.
24. Mayr C, Hemann MT and Bartel DP: Disrupting the pairing between let-7 and Hmga2 enhances oncogenic transformation. Science 315: 1576-1579, 2007.
25. Johnson SM, Grosshans H, Shingara J, et al: RAS is regulated by the let-7 microRNA family. Cell 120: 635-647, 2005.
26. Tsang WP and Kwok TT: Let-7a microRNA suppresses therapeutics-induced cancer cell death by targeting caspase-3. Apoptosis 13: 1215-1222, 2008.
27. Watanabe J, Kushihata F, Honda K, et al: Prognostic significance of Bcl-xL in human hepatocellular carcinoma. Surgery 135: 604-612, 2004.